Estrogen-related Receptor Beta (ERRβ; NR3B2)
|Product Family||Product Number||Product Description||Technical Manual|
|IB08011-32||Human ERRβ Reporter Assay System, 3 x 32 assays in 96-well format||Technical Manual|
|IB08011||Human ERRβ Reporter Assay System, 1 x 96-well format assays||Technical Manual|
|IB08012||Human ERRβ Reporter Assay System, 1 x 384-well format assays|
Estrogen-related Receptor Beta Assay Kit
This Estrogen-related Receptor Beta (ERRβ) assay kit is an all-inclusive firefly luciferase reporter assay system that includes, in addition to ERRβ Reporter Cells, two optimized media for use during cell culture and in diluting the user's test samples, the reference inverse-agonist 4-Hydroxy Tamoxifen, reagents to prepare Luciferase Detection Reagent, a cell culture-ready assay plate, and a detailed protocol.
ERRβ Reporter Cells are prepared using INDIGO’s proprietary CryoMite™ process. This cryo-preservation method yields high cell viability post-thaw, and provides the convenience of immediately dispensing healthy, division-competent reporter cells into assay plates. There is no need for intermediate spin-and-wash steps, viability determinations, or cell titer adjustments.
INDIGO’s ERRβ assay kits feature a luciferase detection reagent specially formulated to provide stable light emission between 5 and 90+ minutes after initiating the luciferase reaction. Incorporating a 5-minute reaction-rest period ensures that light emission profiles attain maximal stability, thereby allowing assay plates to be processed in batch. By doing so, the signal output from all sample wells, from one plate to the next, may be directly compared within an experimental set.
Kits are offered in different assay formats to accommodate researchers’ needs: 3 x 32, 1 x 96, and 1 x 384 assay formats for screening small numbers of test compounds, as well as custom bulk reagents for HTS applications.
Bulk assay reagents can be custom manufactured to accommodate any scale of HTS. Please inquire.
Estrogen-related Receptor Beta Assay Services
The primary application of INDIGO’s cell-based nuclear receptor assays are to quantitatively assess the bioactivity of a test compound as an agonist (activator) or antagonist (inhibition of an agonist response) of a given receptor. Service assays include a positive control reference compound and ‘vehicle’ control for every experiment. A formal study report and all data files are provided to the client upon completion of the study. To receive a quote for your proposed study, complete & submit the online “Request a Quote” form or contact an INDIGO Customer Service Representative to discuss your desired study parameters.
Estrogen-related Receptor Beta Background
INDIGO's Estrogen-related Receptor assay utilizes proprietary human mammalian cells engineered to provide high-level expression of a hybrid form of the Human Estrogen-Related Receptor Beta (NR3B2).
Reporter Cells also incorporate a responsive luciferase reporter gene. Quantifying expressed luciferase activity at the assay endpoint provides a sensitive surrogate measure of changes in ERRβ activity in treated cells. As is true in vivo, these reporter cells express ERRβ in a constitutive state of high-level activity.
Therefore, the principal application of this assay is in the screening of test samples to quantify inverse-agonist or agonist activities that they may exert against human ERRβ.
<Synonyms: Estrogen-related Receptor Beta, ERRβ, ERR beta, ERRb, Human Estrogen-related Receptor Beta, Human ERR beta, NR3B2
Estrogen-related Receptor Beta Assay Data
Dose-response analyses of Human ERRB. ERRB Reporter Cells were treated with varying concentrations of A.) the reference agonists GSK47161 and DY1312 (Tocris), and B.) the inverse-agonists 4-Hydroxy Tamoxifen (provided), DY403 and DY1813. INDIGO’s Live Cell Multiplex assay confirmed that none of the treatment concentrations induced cytotoxicity (data not shown). Averaged relative light units (RLU) and their corresponding values of standard deviation and percent coefficient of variation were determined for each treatment concentration (n = 3). Values of fold-activation (F/A) and fold-reduction (F/R) in ERRB activities were calculated by normalizing respective RLU values from test compound-treated reporter cells to the RLU value of untreated reporter cells. Z’ values were calculated as described by Zhang, et al. (1999). Non-linear regression and respective EC50 and IC50 determination were performed using GraphPad Prism software.
Estrogen-related Receptor Beta Assay Research Areas
Osteoporosis; Circadian Rhythm; Lipid Metabolism and Energy; Environmental Toxicology